Group 1 - The majority of Hong Kong pharmaceutical stocks are experiencing declines, with Hansoh Pharmaceutical falling over 4% [1] - Hansoh Pharmaceutical (03692.HK) decreased by 4.45%, while other companies like Aimeijia Vaccine (06660.HK) and CSPC Pharmaceutical Group (01093.HK) also saw significant drops of 3.98% and 2.72% respectively [1] - Kanglong Chemical (03759.HK) reported a decline of 1.83%, indicating a broader trend of weakness in the sector [1]

Short Selling Ratios - Li Ning-R (82331) has the highest short selling ratio at 100.00% [1][2] - Bank of China Hong Kong-R (82388) follows with a short selling ratio of 97.81% [1][2] - Lenovo Group-R (80992) ranks third with a short selling ratio of 95.62% [1][2] Short Selling Amounts - Alibaba-SW (09988) leads in short selling amount with 2.599 billion [1][2] - Meituan-W (03690) has a short selling amount of 1.626 billion [1][2] - Xiaomi Group-W (01810) follows closely with a short selling amount of 1.622 billion [1][2] Deviation Values - Bank of China Hong Kong-R (82388) has the highest deviation value at 53.64% [1][2] - Lenovo Group-R (80992) has a deviation value of 51.19% [1][2] - Jinyu Group (02009) ranks third with a deviation value of 37.02% [1][2]

Core Viewpoint - The company is facing significant pressure from centralized procurement and medical insurance cost control in Q1 2025, but is expected to see gradual improvement starting from Q2 2025, with projections of achieving three major BD licensing deals exceeding $5 billion each in 2025 [1][2] Group 1: Q1 2025 Performance - In Q1 2025, the company's revenue decreased by 30% year-on-year, excluding BD income, with the prescription drug segment declining by 37% [1] - Key therapeutic areas experienced declines: CNS down 30% due to medical insurance cost control and a 13% price reduction from negotiations; oncology core products saw a 66% drop in sales due to centralized procurement and channel price adjustments [1] - The company recorded 720 million RMB in licensing fee income, primarily from collaborations with AstraZeneca and BeiGene [1] - Revenue from raw materials increased by 15% year-on-year, driven by demand in the VC market and rising product prices, while functional foods and other business revenues fell by 9% due to declining demand and prices for caffeine [1] - The net profit margin improved by 3.1 percentage points to 21.1% due to high-margin licensing income and cost control efforts [1] Group 2: Future Outlook and BD Transactions - The company anticipates gradual improvement in performance starting Q2 2025, driven by increased promotion of Enbip, stabilization from procurement and inventory adjustments, rapid market entry of new products, and additional BD income recognition [2] - Management expects to achieve three large overseas licensing deals in 2025, each exceeding $5 billion, including a comprehensive technology platform licensing deal [2] - The company is advancing a Phase III study for EGFR ADC in second-line EGFR+ NSCLC in China and has initiated studies for third-line EGFR classic mutation NSCLC overseas, with further discussions with the FDA planned for June [2] - Based on optimistic BD income and operating expense forecasts, the company has raised its revenue projections for 2025-2027 by 1.5-7.5% and net profit forecasts by 8-13% [2] - The DCF target price has been adjusted to 7.2 HKD, corresponding to a 14.7x P/E ratio and 1.1x PEG for 2025, indicating that the current stock price reflects the anticipated pressure on 2025 performance and future BD transactions, with limited upside potential [2]

Core Viewpoint - The company reported a significant improvement in revenue and profit in Q1 2025, driven by stable core business performance and the recognition of upfront payments from Lp(a) and MAT2A small molecule BD transactions [1][2]. Group 1: Financial Performance - Q1 2025 revenue reached 7.015 billion yuan, representing a year-on-year decline of 21.9% but a quarter-on-quarter increase of 11% [1]. - Net profit attributable to the parent company was 1.48 billion yuan, down 8.4% year-on-year but up 169% quarter-on-quarter [1]. - The improvement in revenue and profit was attributed to the confirmation of upfront payments from BD transactions and a stabilization in core business revenue [2]. Group 2: Business Development and Pipeline - The company is optimistic about the EGFR ADC clinical trials, with five Phase III trials expected to be conducted domestically and internationally this year [2]. - Positive data from AACR regarding lung cancer overall response rate (ORR) and safety profiles were highlighted, indicating strong potential for market entry [2]. - The company is focusing on HER2-targeted therapies and anticipates the launch of GLP-1 products by 2026 [3]. Group 3: Cost Management and Future Outlook - The company has significantly reduced sales expenses, with a sales expense ratio of 24% in Q1 2025 compared to 33% in Q1 2024 [2]. - The company expects a gradual improvement in revenue and profit throughout 2025, with a conservative estimate of approximately 4 billion yuan in core business profit for the year [2]. - The target price for the company's stock is set at 10.12 HKD, based on a 19x PE ratio for 2025 [3].

Investment Rating - The report assigns a "Buy" rating for CSPC Pharma with a 12-month price target of HK$8.74, indicating an upside potential of 14.7% from the current price of HK$7.62 [13][14]. Core Insights - The report highlights that CSPC Pharma experienced a revenue decline of 22% in Q1, primarily due to a high base in Q1 2024, ongoing pressure from volume-based procurement (VBP), and a 12.5% price cut for NBP injection [1]. - Despite the revenue miss, earnings showed resilience, supported by out-licensing income and significant expense cuts, particularly in selling expenses [1]. - Management has revised its guidance for 2025, focusing on sequential improvement rather than positive sales growth, and plans to pursue three more business development (BD) deals with a potential total deal size exceeding US$5 billion [2][8]. Summary by Sections Revenue and Earnings Performance - CSPC Pharma's sales in Q1 declined by 22% year-on-year, with finished drug sales down 27% year-on-year [1]. - Earnings for Q1 were reported at Rmb1.5 billion, an 8% decrease year-on-year, but were bolstered by Rmb718 million from out-licensing [1]. - Core earnings, excluding BD income, are estimated to have declined by approximately 45% year-on-year [1]. Business Development and Licensing - The company is actively negotiating three potential BD deals, with one expected to close in June, focusing on SYS6010 (EGFR ADC) and other technology collaborations [2]. - In Q1, CSPC Pharma booked US$40 million from the AZ deal and US$60 million from the BeOne deal, with expectations of over Rmb1 billion in additional income from new deals throughout the year [2]. Clinical Development and Pipeline - SYS6010 is prioritized for clinical development, with ongoing phase 3 studies for NSCLC and plans for further trials in various solid tumors [3][7]. - The company is preparing for pivotal studies outside China and aims to apply for breakthrough designation for certain assets [7]. Shareholder Returns and Incentives - CSPC Pharma plans to utilize operational cash flow for R&D and higher dividends, with a share buyback target of up to HK$5 billion over the next 24 months [8]. - A share-based incentive program is set to cover 200-300 key staff, with additional coverage planned for the second half of 2025 [8]. Financial Projections - Earnings estimates have been revised down by 7.7% for 2025 due to lower-than-expected finished drug sales, but the price target has increased from HK$7.84 to HK$8.74 [9]. - Revenue projections for 2025 are set at Rmb30.1 billion, with expectations of gradual recovery in subsequent years [14].

5月30日恒生指数下跌1.20%，报收23289.77点，全天南向资金通过港股通渠道合计净买入96.47亿港 元。 深市港股通前十大成交活跃股中，成交额居首的是阿里巴巴-W，成交金额21.12亿港元；其次是小米集 团-W、石药集团，成交金额分别为18.77亿港元、13.44亿港元。以净买卖金额统计，有7只股为净买 入，净买入金额最多的是理想汽车-W，净买入4.01亿港元，该股收盘上涨3.79%。净卖出金额最多的是 盈富基金，净卖出8.86亿港元，收盘股价下跌1.17%。（数据宝） 证券时报·数据宝统计，5月30日港股通全天合计成交金额为948.53亿港元，成交净买入96.47亿港元。具 体来看，沪市港股通成交金额624.01亿港元，成交净买入81.67亿港元；深市港股通成交金额324.52亿港 元，成交净买入14.79亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，阿里巴巴-W成交额为40.79亿港元，成交金额居 首；其次是腾讯控股、小米集团-W，成交金额分别为35.79亿港元、26.11亿港元。以净买卖金额统计， 美团-W净买入额为17.38亿港元，净买入金额居首，该股收盘股价下跌1.50%。净卖出 ...

Market Overview - The Hong Kong stock market experienced a gap down of 1.2% due to unexpected developments in the trade war, despite initial optimism about tariff negotiations [1] - The U.S. Court of Appeals temporarily suspended a lower court's ruling that prohibited the enforcement of several tariff orders from the Trump administration, providing a temporary reprieve for the administration [1][2] Trade Policy Developments - The Trump administration is considering a two-step strategy to ensure the continuation of its tariff policies, potentially utilizing a rarely invoked clause from the Trade Act of 1974 to impose tariffs of up to 15% for 150 days [2] - U.S. Treasury Secretary indicated that trade negotiations between the U.S. and China are currently stalled, requiring direct involvement from both countries' leaders to reach an agreement [2] Industry Responses - In response to the U.S. trade actions, China announced export controls on seven categories of rare earth materials, which are critical for various industries including automotive and aerospace [3] - The Chinese rare earth sector is expected to see movements in related stocks, such as China Rare Earth (00769) and Jinhui Rare Earth (06680) [3] Pharmaceutical Sector Highlights - The pharmaceutical company CSPC Pharmaceutical Group (01093) announced three potential BD collaborations with a total transaction value nearing $5 billion, with one deal expected to be signed next month [4] - The stock of CSPC Pharmaceutical rose over 6%, reaching a new high for the year, reflecting the growing competitiveness of Chinese innovative drug companies in the global market [4] Shipbuilding Industry Performance - The Chinese shipbuilding industry demonstrated strong resilience, with completion and new order volumes for the first four months of the year reaching 15.32 million deadweight tons and 30.69 million deadweight tons, respectively, maintaining a global market share of 49.9% and 67.6% [8] - Many shipbuilding companies report full order books, with some orders extending to 2029, indicating a sustained positive outlook for the industry [8] Individual Company Insights - China Shipbuilding Defense (00317) reported a significant increase in revenue and net profit for Q1, with net profit growing by 1099.85% year-on-year, driven by increased ship product revenue and improved production efficiency [10] - The company has a robust order backlog, with new orders in Q1 amounting to RMB 12.502 billion, which is 71.64% of its annual target, indicating strong future cash flow and operational performance [10]

Core Viewpoint - The company is in discussions with multiple independent third parties regarding three potential licensing collaborations, particularly focusing on the development, production, and commercialization rights of its core product, EGFR-ADC, which has led to a significant market response with a stock price increase of over 12% following the announcement [1][5]. Group 1: Business Development and Market Response - The potential total payments from the three licensing deals could reach approximately $5 billion, with one deal already in advanced stages expected to conclude by June 2025 [1][4]. - There is a division in market sentiment; some investors believe the value of the ADC platform has been underestimated and that the business development (BD) could act as a catalyst for market capitalization re-evaluation, while others are concerned about the impact of centralized procurement on traditional generic drug business [1][4][6]. - The company’s proactive disclosure of BD progress may be a response to increasing investor inquiries and market concerns, rather than merely a strategy to alleviate performance pressure [2][3]. Group 2: Financial Performance and Challenges - In Q1 2025, the company reported a 21.9% year-on-year decline in total revenue to 7.015 billion yuan, with a significant drop of 65.7% in its oncology business [6][7]. - The revenue from the finished drug segment fell by 27.3%, while the raw material drug segment saw a 14.6% increase, indicating a mixed performance across different business lines [6][7]. - The company’s R&D expenses reached 1.302 billion yuan in Q1 2025, representing an 11.4% increase year-on-year, highlighting its commitment to innovation despite current financial pressures [7]. Group 3: Future Outlook and Market Sentiment - Analysts maintain a cautiously optimistic outlook, predicting that the company’s performance may begin to recover in Q2 2025, with expectations for more significant BD transactions throughout the year [8][9]. - The ongoing negotiations and updates on clinical data are anticipated to clarify the effectiveness of the company's transformation strategy in the coming months [9].

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 21.12 亿元 | +1.15 亿元 | | 小米集团-W(01810) | 18.77 亿元 | +1.73 亿元 | | 石药集团(01093) | 13.44 亿元 | +3.70 亿元 | | 腾讯控股(00700) | 12.27 亿元 | -6024.10 万元 | | 众安在线(06060) | 10.23 亿元 | +5290.10 万元 | | 美团-W(03690) | 9.60 亿元 | +1.83 亿元 | | 理想汽车-W(02015) | 9.59 亿元 | +4.01 亿元 | | 盈富基金(02800) | 8.89 亿元 | -8.86 亿元 | | 中芯国际(00981) | 6.34 亿元 | -1.44 亿元 | | 泡泡玛特(09992) | 5.37 亿元 | +1.27 亿元 | 智通财经APP获悉，2025年5月30日当天，阿里巴巴-W(09988)、腾讯控股(00700)、小米集团-W(01810) 位居沪 ...

Group 1: Market Overview - Northbound trading recorded a net buy of HKD 96.47 billion, with HK Stock Connect (Shanghai) contributing HKD 81.67 billion and HK Stock Connect (Shenzhen) contributing HKD 14.79 billion [1] - The most bought stocks included Meituan-W (03690), China Construction Bank (00939), and Xiaomi Group-W (01810) [1] - The most sold stocks were the Tracker Fund of Hong Kong (02800), Tencent (00700), and SMIC (00981) [1] Group 2: Stock Performance - Alibaba-W (09988) saw a net inflow of HKD 2.77 billion, with buy and sell amounts of HKD 21.78 billion and HKD 19.01 billion respectively [2] - Meituan-W (03690) received a net buy of HKD 19.21 billion, with significant growth in sales during the "Meituan 618" promotion, achieving a year-on-year increase of twofold [6] - Xiaomi Group-W (01810) had a net buy of HKD 6.35 billion, benefiting from strong growth in major appliances and AIoT revenue, which increased by 59% year-on-year [7] Group 3: Sector Insights - China Construction Bank (00939) and Bank of China (03988) received net buys of HKD 13.36 billion and HKD 1.79 billion respectively, indicating a continued interest in domestic bank stocks [6] - The pharmaceutical sector saw Stone Pharmaceutical Group (01093) with a net buy of HKD 6.25 billion, as it engages in potential transactions that could total around USD 5 billion [7] - Ideal Auto-W (02015) received a net buy of HKD 3.55 billion, with expectations of increased production capacity and upcoming model launches [8] Group 4: Notable Sell-offs - SMIC (00981) faced a net sell of HKD 1.44 billion, with guidance indicating a revenue decline of 4%-6% quarter-on-quarter for Q2 2025 [9] - The Tracker Fund of Hong Kong (02800) experienced a net sell of HKD 8.85 billion, attributed to a lack of catalysts in market sentiment and economic conditions [9] - Tencent (00700) saw a net sell of HKD 8.65 billion, reflecting ongoing market challenges [9]